Literature DB >> 9307607

11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping.

R A Weeks1, V J Cunningham, P Piccini, S Waters, A E Harding, D J Brooks.   

Abstract

We compare region of interest (ROI) analytical approaches with statistical parametric mapping (SPM) of 11C-diprenorphine positron emission tomography findings in five patients with Huntington's disease (HD) and nine age-matched controls. The ROI were placed on caudate, putamen, and an occipital reference area. Ratios of striatal-occipital uptake from averaged static images centered at 60 minutes showed a mean 20% reduction in caudate (P = 0.034) and 15% reduction in putamen (P = 0.095) receptor binding in the HD patients. Dynamic data from caudate and putamen ROI, together with a plasma tracer input function, were analyzed using spectral analysis to give regional impulse response functions. Regional data at 60 minutes after impulse showed a mean 29% decrease in caudate (P = 0.006) and 23% decrease in putamen (P = 0.029) opioid binding in the HD cohort. Parametric images of tracer binding also were produced with spectral analysis on a voxel basis. The images of the unit impulse response function at 60 minutes showed a mean 31% decrease in caudate (P = 0.005) and a 26% decrease in putamen binding (P = 0.011) in HD. The voxel-based parametric images were transformed into standard stereotactic space, and a between-group comparison (patient versus controls) was performed with SPM. This approach revealed symmetrical decreases in caudate (peak 40% decrease, z score = 4.38) and putamen opioid binding (peak 24% decrease, z score = 4.686) with additional nonhypothesized changes in cingulate, prefrontal, and thalamic areas. The significance and precision of changes measured with spectral analysis applied to dynamic data sets were superior to ROI-based ratio analysis on static images. The SPM replicated the striatal reductions in opioid binding in HD and detected additional nonpredicted changes. This study suggests that SPM is a valid alternative to conventional ROI analytical approaches for determining binding changes with positron emission tomography and may have advantages over region-based analyses in exploratory studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9307607     DOI: 10.1097/00004647-199709000-00003

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  11 in total

1.  Obsessive-Compulsive Disorder Symptoms in Huntington's Disease: A Case Report.

Authors:  Juan Carlos Molano-Eslava; Angela Iragorri-Cucalón; Gonzalo Ucrós-Rodríguez; Carolina Bonilla-Jácome; Santiago Tovar-Perdomo; David V Herin; Luis Orozco-Cabal
Journal:  Rev Colomb Psiquiatr       Date:  2008-10-01

2.  Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users.

Authors:  R Thomasius; K Petersen; R Buchert; B Andresen; P Zapletalova; L Wartberg; B Nebeling; A Schmoldt
Journal:  Psychopharmacology (Berl)       Date:  2003-03-11       Impact factor: 4.530

3.  Orbitofrontal (18) F-DOPA Uptake and Movement Preparation in Parkinson's Disease.

Authors:  Lucio Marinelli; Arnoldo Piccardo; Laura Mori; Silvia Morbelli; Nicola Girtler; Antonio Castaldi; Agnese Picco; Carlo Trompetto; Maria Felice Ghilardi; Giovanni Abbruzzese; Flavio Nobili
Journal:  Parkinsons Dis       Date:  2015-06-11

Review 4.  Current status of PET imaging in Huntington's disease.

Authors:  Gennaro Pagano; Flavia Niccolini; Marios Politis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-22       Impact factor: 9.236

Review 5.  PET Imaging in Huntington's Disease.

Authors:  Andreas-Antonios Roussakis; Paola Piccini
Journal:  J Huntingtons Dis       Date:  2015

Review 6.  Spectral Analysis of Dynamic PET Studies: A Review of 20 Years of Method Developments and Applications.

Authors:  Mattia Veronese; Gaia Rizzo; Alessandra Bertoldo; Federico E Turkheimer
Journal:  Comput Math Methods Med       Date:  2016-12-05       Impact factor: 2.238

Review 7.  Molecular Imaging Markers to Track Huntington's Disease Pathology.

Authors:  Heather Wilson; Rosa De Micco; Flavia Niccolini; Marios Politis
Journal:  Front Neurol       Date:  2017-01-30       Impact factor: 4.003

Review 8.  Imaging of opioid receptors in the central nervous system.

Authors:  Gjermund Henriksen; Frode Willoch
Journal:  Brain       Date:  2007-11-29       Impact factor: 13.501

9.  Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease.

Authors:  Stéphanie Bissonnette; Mylène Vaillancourt; Sébastien S Hébert; Guy Drolet; Pershia Samadi
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

Review 10.  A Survey of Molecular Imaging of Opioid Receptors.

Authors:  Paul Cumming; János Marton; Tuomas O Lilius; Dag Erlend Olberg; Axel Rominger
Journal:  Molecules       Date:  2019-11-19       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.